ArticleMedical oncology (Northwood, London, England)2013
Serum lemur tyrosine kinase 3 expression in colorectal cancer patients predicts cancer progression and prognosis.
Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 17 citations in OpenAlex.
- LMTK3 as a spatially regulated and stage-dependent biomarker in epithelial ovarian tumorigenesis.Molecular therapy. Oncology · 2026Article
- Evaluation of the Association between LMTK3 Gene Polymorphism and Breast Cancer Risk in the Indian Population.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Lemur tail kinase 3 serves as a predictor of patient outcomes and a target for the treatment of ovarian cancer.Molecular therapy. Oncology · 2024Article
- A revised nomenclature for the lemur family of protein kinases.Communications biology · 2024Review
- The Inhibitory Properties of a Novel, Selective LMTK3 Kinase Inhibitor.International journal of molecular sciences · 2023Article
- Lemur tyrosine kinase-3 (LMTK3) induces chemoresistance to cetuximab in colorectal cancer via the ERK/MAPK pathway.Bioengineered · 2021Article
- The multifaceted role of lemur tyrosine kinase 3 in health and disease.Open biology · 2021Review
- AKT1 Polymorphism (rs10138227) and Risk of Colorectal Cancer in Moroccan Population: A Case Control Study.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathway.FEBS open bio · 2020Article
- Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy.International journal of molecular sciences · 2019Review
- LMTK3 confers chemo-resistance in breast cancer.Oncogene · 2018Article
- Molecular screening and docking analysis of LMTK3and AKT1 combined inhibitors.Bioinformation · 2018Article
- LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer.Molecular medicine reports · 2017Article
- Serum lemur tyrosine kinase-3: a novel biomarker for screening primary non-small cell lung cancer and predicting cancer progression.International journal of clinical and experimental pathology · 2015Article
- Prognostic role of lemur tyrosine kinase 3 in postoperative gastric cancer.Molecular and clinical oncology · 2014Article
- Preoperative serum LMTK3 as a novel biomarker in non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lemur tyrosine kinase-3 (LMTK3) is a member of the families of serine-threonine-tyrosine kinases, which has been suggested to be a possible target and marker of breast cancer. However, its definitive physiopathological function in colorectal cancer (CRC) is poorly understood at present. The aim of this study was to determine the expression levels of preoperative-soluble LMTK3 (sLMTK3) in patients' blood with CRC and to subsequently evaluate whether or not its level in serum can be used to predict cancer progression and prognosis. The expression levels of sLMTK3 were measured by sandwich enzyme-linked immunosorbent assay in blood specimens from 60 patients with CRC and 53 healthy volunteers. As a result, we found that the mean concentration of sKMTK3 in CRC patients was significantly higher than that in healthy volunteers (P = 0.012). The expression levels of sLMTK3 were significantly correlated with histological subtype, depth of tumor invasion, and tumor-node-metastasis (TNM) classification (P = 0.038, 0.021, and 0.049, respectively), but not with sex, age, tumor location, tumor size, or lymph node metastasis. Additionally, Kaplan-Meier survival curves showed that patients with high levels of sLMTK3 had a poorer overall survival rate when compared with those of patients with low levels of sLMTK3 (P = 0.041). Moreover, multivariate analysis demonstrated that sLMTK3 expression and TNM stage were independent prognostic factors for CRC patients (P = 0.047 and 0.008, respectively). These results suggest that serum LMTK3 could be a valuable biomarker for predicting the progression and prognosis of patients with CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.